Background: Human Parvovirus B19 is most known for causing disease in the pediatric population but can also affect adults. Human co-infection with Parvovirus B19 could deteriorate the prognosis of patient with chronic illness. Objectives: This paper attempts to determine the prevalence of Parvovirus B19 in HCV infected patients and to evaluate the impact of Parvovirus B19 on liver enzymes activity of Hepatitis C patients. Study Design: The study population includes 74 chronic HCV (patient group) and 49 cases without viral hepatitis (control group). Nucleic acid of Parvovirus B19 was detected in Serum samples by nested polymerase chain reaction (nested-PCR) method. Results: Parvovirus B19-DNA infection was detected in 28.0% of chronic HCV patients. Parvovirus B19-HCV co-infection caused increasing in Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) activity than in B19-negative HCV patients. Conclusion: We conclude that Parvovirus B19 acted synergistically with HCV by increasing the levels alanine aminotransferase (ALT) and Aspartate aminotransferase (AST).
. Parvovirus B19 is a member of the erythrovirus genus of Parvoviridae family. It infects more than 50% of the adult population all over the world (Adler et al., 2006) [3] . The different diseases of Parvovirus B19 represent direct consequences of its ability to target the erythroid cell lineage (Kumar et al., 2013) [4] . The role of Parvovirus B19 in the evolution of chronic hepatitis from hepatotropic viruses is considered. Chronic Parvovirus B19 associated hepatitis is suspected in immunocompetent adults with compatible serology, suggestive histology and detection of the viral genome in the liver and/or increase of specific circulating cytotoxic T-lymphocytes (Mogensen et al., 2010 ) [5] . The exact association of parvovirus B19 co-infection in CHC infected patients directly correlates with the probability of progression to more severe fibrosis, cirrhosis and hepatocellular carcinoma (Opaleye et al., 2011) [6] .
Objective
The present study aimed to investigate the incidence of co-infection of Human Parvovirus B19 in sera samples from patients (cases with positive HCV infection) and controls (cases with negative HCV infection). It aimed to study the effect of B19 pathogenicity on the changes in the liver functions (like liver enzymatic activity of ALT and AST).
Material and Methods

Study Population
This study (approved by the Ethical Committee of Ain Shams University) consisted of a patient group (n = 74) with chronic viral hepatitis C and a control group (n = 49) without viral hepatitis, all samples were collected from Cairo (Sayed Galal hospital), Sohaj (Sohaj general hospital) and Mansoura (Mansoura University hospital). We evaluated 74 consecutive patients with chronic hepatitis C (mean age 42.5 ± 10.2 years; range: 19 -65; 41 males, 33 females). All of the chronic HCV patients were positive for antibodies against hepatitis C virus (anti-HCV) and serum HCV-RNA. The control group (n = 49; mean age 30.25 ± 7.5 range: 17 -54; 31 males, 18 females) consisted of individuals without viral hepatitis. All of the control patients were negative for anti-HCV and HCV-RNA. The age, sex, alanine aminotransferase (ALT) levels, antibodies against Parvovirus B19 (anti-B19-IgM, anti-B19 IgG), B19-DNA of the serum samples of the cases were assessed and recorded. 
Serological Analysis of Parvovirus B19 Infection
Detection of HCV RNA
RNA was isolated from serum samples as described by Lohr et al., (1995) and El Awady et al., (2006) [7] [8] . Reverse transcription-nested PCR was carried out according to Chomczynski and Sacchi (1992) [9] . Primers used for detecting HCV in clinical samples were purchased from Promega and their sequences were as following: P1: 5'GGTGCACGGTCTACGAGACCTC 3'-P2: 5'AACTACTGTCTTCACGCAGAA 3'-P3: 5' TGCTCATGGTGCACG GTCTA 3'-P4: 5' ACTCGGCTAGCAGTCTCGCG 3'-P5: 5' GTGCAGCCTCCAGGACCC 3' (Madison, WI, USA).
Detection of B19-DNA
Viral nucleic acid DNA was extracted from serum sample using Wizard® DNA purification mini kit, Promega (Madison, USA). Nested PCR of serum samples for detection of B19-DNA was carried according to Pinho et al., (2001) [10] . The reaction mixture of the qualitative PCR contained, in total volume of 25 μl, 0.5 ul of 2 Mm dNTPs mix, 0.75 ul of 25 Mm MgC12, 0.25 ul 2.5 U Taq DNA polymerase, 2.5 ul 5X buffer and 14 ul DW. 5ul of DNA mixed with 2 ul (10 pmol) of each primer. Outer primers: forward p1 (5' AAT ACA CTG TGG TTT TAT GGG CCG 3') and reverse p6 (5' CCA TTG CTG GTT ATA ACC ACA GGT 3'). The second round of the nested PCR was done by 2 ul PCR product of the first round using 10 pmol of each primers Inner primers; forward p2 (5' CCA TTG CTG GTT ATA ACC ACA GGT 3') and reverse p5 (5' CTA AAA ATG GCT TTT GCA GCT TCT AC 3') (Bioneer, Atlantic Avenue, Alameda, USA) for amplification of 185 bp.
Agarose Gel Electrophoresis and Analysis of Nested-PCR Product
Analysis of nested-PCR products were performed according to Aaij and Borst, (1972) [11] . Amplification products of both HCV RT-nested PCR and B19 nested-PCR were visualized after electrophoresis on 2% agarose gel stained with ethidium bromide.
Biochemical Analysis
Biochemical tests, including Alanine amino transferase (normal range, 40 U/L) and Aspartate amino transferase (normal range, 38 U/L) levels were done on all collected samples with commercially available Flex ALAT (GPT) and ASAT (GOT) Kits (Siemens Healthcare Diagnostic Inc., USA). Tests were done according to the instructions of the manufacturer.
Statistical Analysis
All statistical analyses were performed using SPSS statistical software program. Open Journal of Applied Sciences
Differences were considered significant when p ≤ 0.05.
Results
Detection of Anti-B19 Antibodies in Study and Control Groups
From the study group, 42 out of 74 (56.7%) chronic HCV were positive for B19-IgG antibodies (Table 1) . Sera from 17 out of 49 (34.7%) individuals from the control group were positive for B19-IgG antibodies (Table 2) .
Five patients out of 74 (6.7%) chronic HCV were positive for B19-IgM antibodies (Table 1) . Three cases out of 49 (6.1%) from the control group was positive for B19-IgM antibodies ( Table 2 ).
Detection of B19-DNA by Nested PCR
In chronic HCV patients, B19-DNA was positive in 28% ( 
Serum Levels of the Liver Transaminases in the Study Groups
In positive HCV-RNA patient group, serum ALT activity levels was detected as 
Discussion
Human Parvovirus B19 infection is considered a serious disease, because it (2011) [6] reported that, the patients with reactivated B19 infection had lower levels of HBV DNA and higher mean values of serum hepatitis C virus (HCV)
RNA as compared to parvovirus B19 -seropositive patients without reactivation. Open Journal of Applied Sciences
Conclusion
We recommend introducing Parvovirus B19 treatment in HCV patients to prevent rapid deterioration and to slow the progression to liver fulminant liver failure and chronic hepatitis.
